Spero Therapeutics (SPRO) Competitors $2.76 +0.07 (+2.60%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$2.76 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRO vs. EIKN, CADL, CLYM, STRO, and ARVNShould you buy Spero Therapeutics stock or one of its competitors? MarketBeat compares Spero Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spero Therapeutics include EIKN (EIKN), Candel Therapeutics (CADL), Climb Bio (CLYM), Sutro Biopharma (STRO), and Arvinas (ARVN). These companies are all part of the "pharmaceutical products" industry. SPRO vs. EIKNSPRO vs. CADLSPRO vs. CLYMSPRO vs. STROSPRO vs. ARVNHow does Spero Therapeutics compare to EIKN?Spero Therapeutics (NASDAQ:SPRO) and EIKN (NASDAQ:EIKN) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings. Does the media refer more to SPRO or EIKN? In the previous week, EIKN had 4 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for EIKN and 0 mentions for Spero Therapeutics. EIKN's average media sentiment score of 0.99 beat Spero Therapeutics' score of -0.35 indicating that EIKN is being referred to more favorably in the news media. Company Overall Sentiment Spero Therapeutics Neutral EIKN Positive Is SPRO or EIKN more profitable? Spero Therapeutics has a net margin of 24.90% compared to EIKN's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat EIKN's return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics24.90% 35.58% 24.95% EIKN N/A N/A N/A Do insiders & institutionals believe in SPRO or EIKN? 25.6% of Spero Therapeutics shares are owned by institutional investors. 5.5% of Spero Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has higher valuation and earnings, SPRO or EIKN? Spero Therapeutics has higher revenue and earnings than EIKN. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$54.77M2.92$8.57M$0.2411.50EIKNN/AN/AN/AN/AN/A Do analysts prefer SPRO or EIKN? EIKN has a consensus price target of $25.20, indicating a potential upside of 130.98%. Given EIKN's stronger consensus rating and higher possible upside, analysts plainly believe EIKN is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50EIKN 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummarySpero Therapeutics beats EIKN on 6 of the 11 factors compared between the two stocks.How does Spero Therapeutics compare to Candel Therapeutics?Candel Therapeutics (NASDAQ:CADL) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk. Do analysts prefer CADL or SPRO? Candel Therapeutics currently has a consensus target price of $18.00, suggesting a potential upside of 125.28%. Given Candel Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Candel Therapeutics is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 1 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.56Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Is CADL or SPRO more profitable? Spero Therapeutics has a net margin of 24.90% compared to Candel Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -60.42% -41.33% Spero Therapeutics 24.90%35.58%24.95% Which has better valuation & earnings, CADL or SPRO? Spero Therapeutics has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel TherapeuticsN/AN/A-$38.18M-$0.98N/ASpero Therapeutics$54.77M2.92$8.57M$0.2411.50 Do institutionals and insiders hold more shares of CADL or SPRO? 13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by company insiders. Comparatively, 5.5% of Spero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more risk and volatility, CADL or SPRO? Candel Therapeutics has a beta of -0.59, indicating that its share price is 159% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Does the media prefer CADL or SPRO? In the previous week, Candel Therapeutics had 16 more articles in the media than Spero Therapeutics. MarketBeat recorded 16 mentions for Candel Therapeutics and 0 mentions for Spero Therapeutics. Candel Therapeutics' average media sentiment score of 0.44 beat Spero Therapeutics' score of -0.35 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Candel Therapeutics Neutral Spero Therapeutics Neutral SummarySpero Therapeutics beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.How does Spero Therapeutics compare to Climb Bio?Climb Bio (NASDAQ:CLYM) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends. Do insiders and institutionals believe in CLYM or SPRO? 69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by insiders. Comparatively, 5.5% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, CLYM or SPRO? Climb Bio has a beta of 0.02, indicating that its stock price is 98% less volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Do analysts recommend CLYM or SPRO? Climb Bio presently has a consensus price target of $20.30, indicating a potential upside of 84.55%. Given Climb Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Climb Bio is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 1 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 3 Strong Buy rating(s) 3.08Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Does the media prefer CLYM or SPRO? In the previous week, Climb Bio had 4 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for Climb Bio and 0 mentions for Spero Therapeutics. Climb Bio's average media sentiment score of -0.15 beat Spero Therapeutics' score of -0.35 indicating that Climb Bio is being referred to more favorably in the media. Company Overall Sentiment Climb Bio Neutral Spero Therapeutics Neutral Is CLYM or SPRO more profitable? Spero Therapeutics has a net margin of 24.90% compared to Climb Bio's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Climb Bio's return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -31.45% -30.39% Spero Therapeutics 24.90%35.58%24.95% Which has better valuation & earnings, CLYM or SPRO? Spero Therapeutics has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$59.85M-$0.78N/ASpero Therapeutics$54.77M2.92$8.57M$0.2411.50 SummarySpero Therapeutics beats Climb Bio on 9 of the 16 factors compared between the two stocks.How does Spero Therapeutics compare to Sutro Biopharma?Spero Therapeutics (NASDAQ:SPRO) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk. Which has stronger valuation and earnings, SPRO or STRO? Spero Therapeutics has higher earnings, but lower revenue than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$54.77M2.92$8.57M$0.2411.50Sutro Biopharma$99.61M4.25-$191.09M-$11.04N/A Do analysts recommend SPRO or STRO? Sutro Biopharma has a consensus target price of $48.25, indicating a potential upside of 88.70%. Given Sutro Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Sutro Biopharma 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.00 Does the media favor SPRO or STRO? In the previous week, Sutro Biopharma had 21 more articles in the media than Spero Therapeutics. MarketBeat recorded 21 mentions for Sutro Biopharma and 0 mentions for Spero Therapeutics. Sutro Biopharma's average media sentiment score of -0.17 beat Spero Therapeutics' score of -0.35 indicating that Sutro Biopharma is being referred to more favorably in the news media. Company Overall Sentiment Spero Therapeutics Neutral Sutro Biopharma Neutral Which has more risk and volatility, SPRO or STRO? Spero Therapeutics has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market. Comparatively, Sutro Biopharma has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market. Do institutionals & insiders have more ownership in SPRO or STRO? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are held by institutional investors. 5.5% of Spero Therapeutics shares are held by insiders. Comparatively, 3.6% of Sutro Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is SPRO or STRO more profitable? Spero Therapeutics has a net margin of 24.90% compared to Sutro Biopharma's net margin of -154.21%. Spero Therapeutics' return on equity of 35.58% beat Sutro Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics24.90% 35.58% 24.95% Sutro Biopharma -154.21%N/A -69.20% SummarySutro Biopharma beats Spero Therapeutics on 10 of the 17 factors compared between the two stocks.How does Spero Therapeutics compare to Arvinas?Spero Therapeutics (NASDAQ:SPRO) and Arvinas (NASDAQ:ARVN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership. Does the media refer more to SPRO or ARVN? In the previous week, Arvinas had 4 more articles in the media than Spero Therapeutics. MarketBeat recorded 4 mentions for Arvinas and 0 mentions for Spero Therapeutics. Arvinas' average media sentiment score of 0.18 beat Spero Therapeutics' score of -0.35 indicating that Arvinas is being referred to more favorably in the news media. Company Overall Sentiment Spero Therapeutics Neutral Arvinas Neutral Is SPRO or ARVN more profitable? Spero Therapeutics has a net margin of 24.90% compared to Arvinas' net margin of -247.54%. Spero Therapeutics' return on equity of 35.58% beat Arvinas' return on equity.Company Net Margins Return on Equity Return on Assets Spero Therapeutics24.90% 35.58% 24.95% Arvinas -247.54%-44.38%-28.38% Which has better earnings & valuation, SPRO or ARVN? Spero Therapeutics has higher earnings, but lower revenue than Arvinas. Arvinas is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpero Therapeutics$54.77M2.92$8.57M$0.2411.50Arvinas$89.40M6.56-$80.80M-$3.32N/A Do analysts recommend SPRO or ARVN? Arvinas has a consensus price target of $14.69, indicating a potential upside of 61.63%. Given Arvinas' stronger consensus rating and higher possible upside, analysts plainly believe Arvinas is more favorable than Spero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50Arvinas 3 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.36 Which has more volatility and risk, SPRO or ARVN? Spero Therapeutics has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Arvinas has a beta of 1.79, meaning that its stock price is 79% more volatile than the broader market. Do institutionals and insiders have more ownership in SPRO or ARVN? 25.6% of Spero Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Arvinas shares are held by institutional investors. 5.5% of Spero Therapeutics shares are held by company insiders. Comparatively, 7.3% of Arvinas shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryArvinas beats Spero Therapeutics on 10 of the 16 factors compared between the two stocks. Get Spero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRO vs. The Competition ExportMetricSpero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$159.81M$3.37B$6.40B$12.31BDividend YieldN/A2.28%2.76%5.31%P/E Ratio11.5018.9321.0025.66Price / Sales2.92325.37556.1383.75Price / Cash17.68131.8944.5756.72Price / Book3.037.1110.377.14Net Income$8.57M$24.45M$3.56B$335.72M7 Day Performance-1.08%3.32%5.10%3.03%1 Month Performance-1.43%2.13%3.58%2.88%1 Year Performance296.38%63.43%34.18%35.20% Spero Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPROSpero Therapeutics1.3779 of 5 stars$2.76+2.6%N/A+295.4%$159.81M$54.77M11.50150EIKNEIKNN/A$10.86-7.6%$25.20+132.0%N/A$585.73MN/AN/A384News CoverageGap UpCADLCandel Therapeutics4.0294 of 5 stars$7.83-0.9%$18.00+129.9%+47.4%$574.07MN/AN/A60Analyst RevisionGap DownCLYMClimb Bio3.0094 of 5 stars$9.66-2.3%$20.30+110.3%+816.7%$553.76MN/AN/A9STROSutro Biopharma3.0566 of 5 stars$33.13-3.9%$48.25+45.6%+183.3%$550.12M$102.48MN/A240Analyst DowngradeAnalyst Revision Related Companies and Tools Related Companies EIKN Alternatives Candel Therapeutics Alternatives Climb Bio Alternatives Sutro Biopharma Alternatives Arvinas Alternatives Valneva Alternatives Kyverna Therapeutics Alternatives Tectonic Therapeutic Alternatives Aquestive Therapeutics Alternatives Prime Medicine Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRO) was last updated on 5/23/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
